A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Status
- COMPLETED
- Phase
- PHASE2
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
- Status
- RECRUITING
- Phase
- NA
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
- Status
- RECRUITING
- Phase
- PHASE2
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Status
- RECRUITING
- Phase
- PHASE2
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
- Status
- TERMINATED
- Phase
- PHASE2
REVIVE (Response to the Ebola Virus Vaccine)
- Status
- RECRUITING
- Phase
- PHASE4
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
- Status
- RECRUITING
- Phase
- PHASE2